Navigation Links
Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent
Date:11/1/2007

HAYWARD, Calif., Nov. 1 /PRNewswire/ -- Arete Therapeutics Inc. today announced the initiation of a phase 1 clinical trial for its lead compound, AR9281, for the treatment of hypertension. AR9281 is a "first-in-class," orally-active inhibitor of soluble epoxide hydrolase (s-EH), a novel target for the treatment of hypertension. The trial will enroll up to 32 healthy adult volunteers and will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics for single ascending doses of AR9281.

"AR9281 inhibits s-EH, an enzyme that plays a key role in the cytochrome P450 pathway of arachidonic acid metabolism, and offers a unique mechanism of action as an antihypertensive agent," said Dinesh V. Patel, Ph.D., president and chief executive officer of Arete Therapeutics Inc. "We believe this first-in-class compound has great potential to be a unique 'antihypertensive-plus' drug that not only lowers blood pressure but also offers end organ protection of the heart and kidney, and protection against vascular inflammation."

"The preclinical safety and efficacy profile of AR9281 is very encouraging and provided a solid basis for the initiation of the clinical development phase of this new compound class," commented Randall Whitcomb, M.D., chief medical officer of Arete Therapeutics Inc. "We look forward to reporting results from the initial phase 1 clinical trial in 2008."

Arete Therapeutics' phase 1 single ascending dose, placebo-controlled clinical trial in healthy volunteers will obtain initial safety and tolerance information as well as detailed blood pressure measurements. Levels of s-EH specific biomarkers will be analyzed together with typical inflammatory markers as part of the pharmacodynamic assessment. Following successful completion of the single dose study, Arete plans to initiate a multiple dose phase 1 study, a food effect study, and studies in special populations.

About AR9281

AR9281 is a novel small molecule inhibi
'/>"/>

SOURCE Arete Therapeutics Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. VBI Provides Potential Targets to Diabetes Therapeutics
2. CELL THERAPEUTICS PAYS Heavily to Resolve Dispute FOR ALLEGED ILLEGAL MARKETING OF CANCER DRUG
3. Bird Flu: Orissa Initiates Protective Measures
4. Biota Initiates Drug Testing War against Common Cold
5. Russia Initiates Mass Vaccination Of Poultry To Restrict Bird Flu
6. Government Initiates A Program To Curb HIV
7. Alteon Initiates Phase 2 Trial of ALT-2074 in Diabetes and Haptoglobin 2-2
8. Peregrine Pharmaceuticals Initiates Patient Enrollment In New Cotara(R) Brain Cancer Trial
9. Maxygen Initiates Phase IIa Clinical Trial of MAXY-G34 in Breast Cancer Patients
10. FDA approves Phase 0 trial which tests experimental drugs on humans
11. SARS-Free Taiwan to Mark End Phase of Global Fight
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... California (PRWEB) March 06, 2015 Johnson ... million jury verdict on March 5, 2015 in Superior ... According to court documents, a jury of 12 awarded ... suffered from being implanted with an Ethicon TVT Abbrevo ... nine men and three women also awarded $5 million ...
(Date:3/6/2015)... (PRWEB) March 06, 2015 Magellan Rx ... only comprehensive source for key trends and statistics on ... medical injectables. Executives from Magellan Rx Management will discuss ... Report: Discover Your Hidden Specialty Drug Spend,” a complimentary ... Services, Inc. , Specialty drug spend makes up more ...
(Date:3/6/2015)... 2015 The Gluten-Free Certification Program ... is pleased to announce that Dufflet Pastries, the ... expanded their product line of gluten-free treats certified ... and as satisfying as any of their other ... never contains hydrogenated fats or oils, artificial flavours, ...
(Date:3/6/2015)... Dr. Mark Sowell recently returned from leading a ... programs for advanced education in the field of dentistry, Spear ... As a visiting faculty member of this prestigious institution, Dr. ... he visits Spear Education to participate in a specialized workshop. ... training only the top 10% and those willing to sacrifice ...
(Date:3/5/2015)... From Oct. 5-10, Mumbai, India will serve as ... These dates include the following activities:, ... October 6: Conference Day 1, ending with a Fashion ... 2, ending with Local Entertainment and Dinner , ... Materials Meetings , October 9-10: Textiles in India ...
Breaking Medicine News(10 mins):Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 3Health News:Atlantic Information Services, Magellan Rx Management Partner on Complimentary Webinar Outlining Key Findings of New Medical Pharmacy Trend Report 2Health News:Dufflet Pastries® Impressive Collection of Brownies, Cakes, Pies and Cakelets® Now Includes a Gluten-Free Line Certified By the GFCP. 2Health News:Dufflet Pastries® Impressive Collection of Brownies, Cakes, Pies and Cakelets® Now Includes a Gluten-Free Line Certified By the GFCP. 3Health News:Dufflet Pastries® Impressive Collection of Brownies, Cakes, Pies and Cakelets® Now Includes a Gluten-Free Line Certified By the GFCP. 4Health News:Plano Dentist Teaches Dentists from Around the Globe at Spear Education 2Health News:Textile Exchange Announces the 2015 Textile Sustainability Conference Dates 2
... the 1960s, surgeons experimented by transplanting chimpanzee organs into humans ... received a baboon heart and survived 20 days. // Since ... source for organs, tissues and cells to treat various diseases, ... the controversy surrounding cross-species transplant -- also known as xenotransplantation. ...
... diabetes is important because lifestyle changes and medication can prevent ... glucose tolerance test is used to identify high-risk individuals for ... study finds a cluster of risk //factors known as metabolic ... other risk factors. ,Metabolic syndrome has been shown ...
... osteoarthritis and rheumatoid arthritis cause joint pain and //stiffness ... no effective treatment to repair damaged cartilage. ... drug to prevent the onset of arthritis. The research ... a pivotal role in the onset of the condition. ...
... births of their first two children are more likely to deliver ... the same partner.// These babies are also ... results are the same even when researchers take into account the ... of birth. ,Researchers speculate that women who change ...
... the right mattress can make a difference. //Three-quarters of physicians ... a new study says they could be wrong. The new ... pain. ,Physicians often get frustrated when patients ask ... back pain. Few studies have been done on this issue ...
... night outlawed tobacco use in the Commonwealth's restaurants, taverns, ... on Sunday liquor-store sales as the House and Senate ... ,Working until nearly midnight, lawmakers also approved a sales ... thereby pumping up the state's flagging economy, and approved ...
Cached Medicine News:Health News:Animals Can give us a second chance at life 2Health News:Predictors for Type 2 Diabetes 2Health News:Changing Partners may put Expectant Mothers at Risk 2Health News:Senate assures ban on smoking 2Health News:Senate assures ban on smoking 3Health News:Senate assures ban on smoking 4
(Date:3/6/2015)...  AbbVie (NYSE: ABBV ) will participate ... March 12, 2015. Richard A. Gonzalez , chairman ... and answer session at 8:30 a.m. Central time. ... be accessible through AbbVie,s Investor Relations Web site at ... will be available later that day. ...
(Date:3/6/2015)... Alemania, 6 de marzo de 2015 ... de gestión empresarial de imagen médica, fortalece su ... nombramiento de Randolph Sternberg como director ... como director de operaciones. Logo - ... será responsable de las ventas y desarrollo ...
(Date:3/5/2015)... 5, 2015   MeridianRx earned highest ... seven optional leading indicators during its recent URAC ... "We are very proud of earning this level ... , Chief Operating Officer of MeridianRx. "It is ... to transparency, flexibility and innovation." URAC,s ...
Breaking Medicine Technology:TeraRecon fortalece su posición en EMEA 2TeraRecon fortalece su posición en EMEA 3MeridianRx Earns Highest URAC Accreditation Status 2
... May 4 With today,s announcement of a new ... leadership in health information technology (HIT) has now attracted $49.5 ... Reinvestment Act (ARRA). , , ... The latest grant comes through the Beacon Communities Cooperative Agreement ...
... NEW ORLEANS , May 4 ... with Traficet-EN™ (CCX282-B) in the Maintenance period of PROTECT-1 ...   Traficet-EN maintained a clinical remission rate (Crohn,s Disease ... in Crohn,s patients over the course of 36 weeks, ...
Cached Medicine Technology:Total Federal Grant Funds for Indiana Health Information Technology Efforts Climb to Nearly $50 Million; Latest $16 Million Installment Spotlights Indiana Health Information Exchange in Delivering Higher Quality and Higher Value Healthcare Through M 2Total Federal Grant Funds for Indiana Health Information Technology Efforts Climb to Nearly $50 Million; Latest $16 Million Installment Spotlights Indiana Health Information Exchange in Delivering Higher Quality and Higher Value Healthcare Through M 3Total Federal Grant Funds for Indiana Health Information Technology Efforts Climb to Nearly $50 Million; Latest $16 Million Installment Spotlights Indiana Health Information Exchange in Delivering Higher Quality and Higher Value Healthcare Through M 4ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohn's Disease at the Digestive Disease Week (DDW) 2010 Conference 2ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohn's Disease at the Digestive Disease Week (DDW) 2010 Conference 3ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohn's Disease at the Digestive Disease Week (DDW) 2010 Conference 4ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohn's Disease at the Digestive Disease Week (DDW) 2010 Conference 5ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohn's Disease at the Digestive Disease Week (DDW) 2010 Conference 6
... Proven ergonomic design reduces hand fatigue, prevents injury. Dry seal technology. No ... 0.2-2 Inaccuracy (%) ... Imprecision(%) ... 0.01 Dimensions: ...
... improved ergonomics for today's exacting laboratory ... finger rest and the large display ... Finnpipette Digitals also feature soft-touch tip ... pend.) and super blow-out for 0.2 ...
... Pipetman Ultra is a fully adjustable, air-displacement ... It is the latest member of the ... characteristics: robustness, accuracy, and precision. We also ... feedback from our customers. Eight models cover ...
Developed specifically for the 5000/5500 ultrasound consoles....
Medicine Products: